Biomedical research and mining of the poor:

The Need for their exclusion 

Dr. R. R. Kishore, MD, LLB,

e.mail:  rrkishore4@gmail.com

  

Abstract

Almost all ethical guidelines and legislative policies concerning biomedical research involving human subjects contain provisions about relevance of research for the participating populations, informed consent, adequate care for research induced injuries and several other safeguards but the poor continues to suffer. Globalization has further aggravated poor’s  vulnerability by exposing him to international markets.  Since the developing countries are abode of higher population of poor they have become the unholy mines of this human ore for researchers. In this paper I examine various dimensions of poverty and analyze the international ethical responses in the area of biomedical research involving human  subjects in order to determine their adequacy to protect the poor against exploitation and misuse and conclude that in view of poor’s inherent and extreme vulnerability and the failure of ethical pronouncements to protect them from misuse and exploitation,  they should be excluded from being enrolled as research subjects

Kew words.  Research, Poor, vulnerability, inducement, exploitation, exclusion

Introduction

The 2002 International Ethical Guidelines for Biomedical Research Involving Human Subjects, published recently by CIOMS are unique at least in one respect. These guidelines express serious concern about “Research in populations and communities with limited resources” (Guideline 10), “Equitable distribution of burdens and benefits in the selection of groups of subjects in research” (Guideline 12), and “”Research involving vulnerable persons” (Guideline 13) and recognize that “Impoverished groups have been overused because of their willingness to serve as subjects in exchange for relatively small stipends” (emphasis added) and observe that the “Overuse of certain groups such as the poor or the administratively available, is unjust for several reasons. It is unjust to selectively recruit impoverished people to serve as research subjects simply because they can be more easily induced to participate in exchange for small payments. In most cases, these people would be called upon to bear the burdens of research so that others who are better off could enjoy the benefits”  But, the guidelines are not in favour of excluding such persons from research protocols because “It would not be unjust to selectively recruit poor people to serve as research subjects in research designed to address problems that are prevalent in their group” (1)  I find an inherent paradox in this approach and feel that the enrolment of the poor as a research subject is violative of all the three basic ethical principles governing biomedical research namely “respect for persons”, “beneficence” and “justice” (2) In this context the UNAID Guidance Document rather offers a ray of hope for the poor. The Document takes a more objective and definite  view of the ground reality stating, “In some potential research populations (countries or communities), conditions affecting potential vulnerability or exploitation may be so severe that ensuring adequate safeguards is not possible. In such populations, HIV preventive vaccine research should not be conducted” (emphasis added) (3) . “India is fast becoming a hotbed of clinical research” and the business “is growing at almost 100% a year”.  It is estimated that the country “can contribute 20% of the global CRO revenues  by 2010”  which is expected  to be “over $ 50 billion”.  ”The human subjects are available for “Rs. 2500-4000 each”  i.e., nearly $ 50-80 (4) The country is on the verge of starting HIV vaccine trials and, as such, it is high time the ethical issues in this regard are completely sorted out. For various reasons as stated in this article I argue that the inherent  and extreme vulnerability of the poor calls for evolution of much clearer and unambiguous ethical paradigms excluding them from biomedical research.

Poor and his world

Before I go further, I may clarify that in this paper I use the expression “poor” for a person who is devoid of any kind of “assets” i.e., “physical  (e.g. housing);  natural (land, water); human (education, skills); financial (saving account); and social (membership in social networks that increase access to information or resources)” (5) Thus, poor  is not only devoid of money. He is without a face. That makes him poorer.

 “Of the world’s 6 billion people, 2.8 billion – almost half – live on less than $2 a day, and 1.2 billion – a fifth – live on less than $1 a day, with 44 percent living in South Asia ” (6) (p3)  “Poor people live without fundamental freedoms of action and choice that better-off take for granted” (7) and they “are very vulnerable to abuses of their rights” (8) Trade in poor is highly organized. Clinical centers, pharmaceutical industry, medical professionals and the rich have simply to send their requirement to the right agency and the human “stuff” is ready for an agreed price. The deal is mostly impervious to legal action as the “Legal systems, the product of power relations between different groups in society, typically focus on protecting

the interests of those with political strength and representation.” “Even when the legal system is well run, poor people face constraints in using it” (9) For the poor “vulnerability is a graver concern” because “One slip could send them deeper into poverty” (10) Poverty also includes “exposure to risk – and voicelessness and powerlessness” (11) and the act of “reducing poor people’s vulnerability to risk” enhances  their insecurity. (12) Physical impairment or loss of health is not the only consequence of research induced injuries. They may lead to severe socio-economic consequences such as stigmatization, ostracization, loss of job and income and the poor, despite “free medical treatment ‘ and “financial or other assistance” or “compensation” ) (13) and assurance that the risk involved “can be satisfactorily managed” (14) may not be able to cope with the ensuing adversities and deprivation. Research may thus lead to total and irreversible loss of poor’s “capabilities” (15)

Poverty is a complex phenomenon. It breeds many negative forces such as Illiteracy, superstition, Ill health, social bias, Injustice, dependency, genderization, outsized families and migration, enhancing poor’s  vulnerability.  Media is full of disquieting reports indicating exploitation of the poor for organ removal, womb hiring (surrogacy), sale of dead bodies, sale of children, sale of foeti, DNA sampling, clinical research and experimentation. It is very clear that the international pronouncements affirming human dignity  and individual autonomy as essential components of contemporary ethics have failed to protect the poor. Healthcare has thus emerged as a new threat to already oppressed and voiceless poor. Since the developing countries are the abode of higher population of poor they have become the unholy mines of this human ore. Recognition of these dimensions of poverty is essential in order to truly translate the assurances in to reality.

Contemporary responses

Primacy of the human being is a uniformly recognized principle and the “ interests and welfare of the human being shall prevail over the sole interest of society or science” (16)  An “intervention may only be carried out on a person who does not have the capacity to consent, for his or her direct benefit. (emphasis added) (17)  Human dignity contemplates that human beings are not “considered by science  as objects” (18) Principle No. 2.3 as enshrined in the ICH/GCP Guidelines states, “The rights, safety sand well-being of the trial subjects are the most important considerations and should prevail over the interests of science and society”  and  while defining vulnerable subjects the guidelines include “unemployed or impoverished persons” (19)  According to the revised Declaration of Helsinki “In medical research on human subjects, considerations related to the well-being of the human subjects should take precedence over the interests of science and society” (20) The poor  possesses the same human rights as other sections of the society and as such is entitled to protection of his/her person  and cannot be “subjected to arbitrary interference with his  privacy, family ..” (21) No research or research applications “should prevail over respect for human rights, fundamental freedoms and human dignity of individuals or, where applicable, of groups of people” (22)

Respect for persons includes “the requirement to protect those with diminished autonomy”. (23)It is very difficult for the poor to maintain his/her autonomy because he/she  may be lured into research by small attractions and “ inducements that would ordinarily be acceptable may become undue influences” in his/her case. “Given their dependent status and their frequently compromised capacity for free consent, they should be protected against the danger of being involved in research solely for administrative convenience, or because they are easy to manipulate as a result of their illness or socioeconomic condition.” (24) “The offer of

excessive financial compensation, bribes, or unrealistic promises may constitute coercion, especially if the subject is vulnerable because of  social factors such  as poverty or ethnic background”.   “Voluntariness  in informed consent may be inhibited  when there are social status and social class differences between investigators and potential subjects” (25) Researchers admit that in the context of disadvantaged and illiterate population of developing countries “Informed consent is a joke” and if ethical issues are not adequately addressed the situation “can literally be life threatening” (26) The National Bioethics Advisory Commission  while emphasizing the need for “voluntary” informed consent and  selection of the participants “equitably” recommends that the “U. S. government  should not sponsor or conduct clinical trials that do not at a minimum provide”, interalia, “equitable distribution of the  burdens and benefits of research”. The Commission states that, “in countries  in which extreme poverty afflicts so many, primary  health care services  generally are inadequate, and a majority of the population is unable to gain access  to the most basic and essential health products and services. As a result of these difficult conditions, the people in these countries  are often more vulnerable in situations (such as  clinical trials) in which the promise of better health seems to be within reach” The Commission further states that the principle of justice requires that “a population, especially vulnerable one, should not be the focus of research unless some of the potential benefits of the research will accrue to that group after the trial” (27) In the earlier (pre-revised) CIOMS Guidelines (28) there was a note of caution about subject’s  “undue inducement”  (Guidance 4) and inability to consent because “some of them may be relatively incapable of informed consent because they are illiterate, unfamiliar with the concepts of medicine held by the investigators or living in communities in which the procedures typical of informed consent discussions are unfamiliar or alien to the ethos of the community”  (Commentary on Guideline 8)

The importance of informed consent is aptly reflected in the Nuremberg Code which states, “The voluntary consent of the human subject is absolutely essential. This means the person involved should have legal capacity  to give consent; should be so situated as to be able to exercise free power of choice, without the intervention of any element of force, fraud, deceit, duress, overreaching, or other ulterior form of constraint or coercion; should have sufficient knowledge and comprehension of the elements  of the subject matter involved as to be enable him to make an understanding and enlightened decision”  (29) (emphasis added)  According to this definition, poor is not qualified and competent to give informed consent because he/she is ‘so situated’ that he/she he/she is under “constraint’ and “duress’, does not have “power of choice”  and cannot make an “understanding and enlightened decision”.

There is growing realization that the “profit motive has found its way into basic science and research and development” (30) and the “background fear is a breach of distributive justice, since products that disadvantaged populations bear the burden of testing are likely to be marketed in affluent countries and be unavailable to populations of poor countries that served as testing sites” (31) The research should be conducted “under conditions that no person or persons become  a mere means for the betterment of others” (32) Although there is increasing awareness to honour the participant’s “right to receive compensation or indemnity” (33) in the event of research induced damages but the poor are not capable of claiming such remedies. “Medical research is only justified if there is a reasonable likelihood that the populations in which the research is carried out stand to benefit from the results of the research” (34) This principle makes it clear that it is unethical to subject the persons to research in respect of products which are not affordable by them owing to high costs. The persons who cannot afford bare necessities of life  such as  water, food, cloths and shelter  cannot even think of buying medicines. “It is more useful to identify the particular aspects of social context that create conditions for exploitation of increased vulnerability  for the pool of participants that has been selected” (35) Poverty is most important of all the social contexts and as such, the poor should not be included in medical research. 

“At the economic level, medicine has become a source of money, profits and jobs” and “a steadily growing inequitable gap of rich and poor is gaining the best of medicine” (36) “Third party payers are playing growing role in access to research” (37) and the “impoverished partner is hastily asked to sign on the dotted line” (38) “Unfortunately the history of research involving human subjects contains chapters on the misuse or serious abuse of research subjects” and “the principle of respect for human dignity entails high ethical obligations to the vulnerable populations” (39) The possibilities  of impairment of informed consent in situations of  “dependent” or  “unequal power relationships between participants and researchers” are well recognized. (40). Acknowledging the fact that the research into “Aboriginal health has failed to address” the “poor level of health adequately, but has often concerned itself primarily with matters of interest to science or to white people” and the Aboriginal and Torres Strait Islander groups are “more vulnerable than other human groups in Australia to exploitation by persons conducting research”,  the National Health and Medical Research  Council of Australia lays down that research involving “disadvantaged” is permissible only when it is “potentially useful” to that group (42) One of the “fundamental moral commitment” of clinical research involving human  subjects is “to preserve and protect the dignity and health interests of research subjects” (40) While expressing serious concern over the “inequalities” between external sponsors of research and the developing countries and the “real risk of exploitation” the Nuffield Council of Bioethics describes “the duty not to exploit the vulnerable” as one of the “four principles which form the ethical framework” of their report.  (43)

Discussion

Almost all the pronouncements relating to biomedical research involving human subjects have certain common concerns namely, the rights and dignity of the individual is supreme; the interests of the research subjects should take precedence on any other interest; only those subjects should be made to participate who are competent to give voluntary, informed and free consent and the subject included in the research should be capable of enjoying the fruits of the research

In the event of poor’s participation in research, none of the above concerns can be effectively addressed because of  their peculiar circumstances including failure to give voluntary and informed consent owing to  various factors such as, socio-economic dependency, material inducement, inability to understand, perpetual duress and voicelessness. Research induced injuries will cause disability leading to loss of income which in turn will deprive the subject and his/her dependents of food, shelter and  healthcare thereby adding to the existing burden of disease and ill health, adversely affecting the global resources.  Risk in case of poor is greater because of ill health and compromised state of  immune system and there is also increased “risk of social and psychological harm” (44) Exclusion of the poor therefore is not only a moral obligation, it also constitutes a functional imperative of the healthcare policies. Furthermore, it ought to be remembered that the poor are not going to enjoy the fruits of research owing to their financial incapability. Biomedical research involving human subjects is not merely a scientific pursuit. It is  part of a political, economic and commercial activity with substantial possibilities of dehumanization, injustice and exploitation. Transformation of the world from state owned or mixed economies to market economies has further intensified the vulnerability of the poor. Capacity building of the poor therefore should be the first step towards their involvement in main-stream activities like biomedical research. This means imparting them parity with well-to-do sections of the society by economic, educational and social upliftment. Poverty, as such, is a structural constraint to ethical conduct of biomedical research on human subject.  If we aspire to conduct clinical trials founded on the “very best Good Clinical Practice” (45) and if we wish to ensure that “the dignity, rights, safety, and well-being of research participants are promoted” (emphasis added) (46) and “the dignity and worth of the human person” (47) is maintained , the “clinical trial business” (48) has to be seen in this realistic and humane background.

Conclusion

Medicine is not pure science. It is a social pursuit, embracing in its fold concepts of right and wrong. Values therefore assume predominant role. Poverty-health nexus is  the greatest challenge in achieving the  goal of “Health for all”.  Welfare of the poor is thus an essential component of contemporary healthcare strategies. The ethico-legal pronouncements regulating biotechnology and healthcare must be revised accordingly. Following stipulations must constitute a mandatory condition in all regulatory policies concerning biomedical research in order to preempt the exploitation of the poor.

     “The poor i.e., a person devoid of means to afford basic necessities of life such as food, clothes,             shelter, water, sanitation, or a person who is confronted with economic hardships to the extent of           reducing his/her life below a dignified existence will not be subjected to any biomedical research         except when such research is necessary in the interest of that person or an immediate family member      namely the spouse, mother, father, child, brother or sister”. This provision can be applied through a         two pronged strategy: (1) Every research protocol must have a provision to ascertain the economic         status of the research subject i.e. his income, cost of living in the host country and number of                 dependents on the subject. (2) The minimum income of research subjects must be defined.  Those         who fall below the defined level must be excluded from the research

 References

 1.    International Ethical Guidelines for Biomedical Research Involving Human Subjects, prepared by the Council for International Organizations  of Medical Sciences in collaboration with World Health Organization, Geneva 2002, Commentary on Guideline 12

 2.    Ethical Principles and Guidelines for the Protection of Human Subjects of Research, The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, April 18, 1979, the Belmont Report

 3.    Ethical Considerations in HIV Preventive Vaccine Research,  UNAIDS Guidance Document, May, 2000 p7

 4.    P. Hari & Gina Singh. “The booming business of Drug Testing” Businessworld, Volume 22 Issue 20; 7-13 October 2002

 5.    “A User’s Guide to Poverty and Social Impact Analysis”, World Bank Poverty Reduction Group (PRMPR) and Social Development Department (SDV), Work in progress Draft for Comment, April 19 2002, p9

 6.    World Development Report 2000/2001  Attacking Poverty, published by the World Bank, P3

 7.    Ibid, p1

 8.    Ibid, p102

 9.    Ibid, p103

 10.   Ibid, p138

 11.   Ibid, p15

 12.  Ibid, p3

 13.  Guideline 19,  International Ethical Guidelines for Biomedical Research Involving Human ubjects, prepared by the Council for International Organizations  of Medical Sciences in collaboration with World Health Organization, Geneva, 2002

 14.  Ethical Principles for Medical Research Involving Human Subjects, World Medical Association  Declaration of Helsinki, October 2000, S. No. 17, Basic Principles for All Medical Research

 15.  Amartya Sen. “Development as Freedom” New York: Knopf Amaratya Sen’ defines person’s capabilities as “the substantive freedoms he or she enjoys to lead the kind of life he or she values”

 16. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine, Oviedo, 4 April 1997, (Article 2)

 17.  Ibid (Article 6)

 18.  Report on Confidentiality and Genetic Data, by the Working Group of the IBC, UNESCO, July 2000)

 19.  Guidelines for Good Clinical Practice, ICH Harmonised Guidelines, 17January 1997, 1.61

 20.  Ethical Principles for Medical Research Involving Human Subjects, adopted by the 52nd General Assembly of World Medical Association, Edinburgh, Scotland, October, 2000, Para. 5

 

21.  Universal Declaration of Human Rights, adopted by the General Assembly Of United Nations on 10 December 1948, Article 12

 22.  Universal Declaration on the Human Genome and Human Rights, UNESCO, 11 November, 1997, Article 10  

 23.  Ethical Principles and Guidelines for the Protection of Human Subjects of Research, The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, April 18, 1979, the Belmont Report

 24.  Ibid

 25.  Patricia A. Marshall. “The Relevance of Culture for Informed Consent in U.S.-Funded International Health Research”  Ethical and Policy Issues in International Research:  Clinical trials in Developing Countries. Report and Recommendations of the National Bioethics Commission, Bethesda, Maryland, April 2001, Vol. II,  p. C-6

 26.  Nancy Kass and Adnan A. Hyder. “Attitudes and Experiences of U.S. and Developing Countries Investigators Regarding U.S. Human Subjects Regulations. Ethical and Policy Issues in International Research:  Clinical trials in Developing Countries. Report and Recommendations of the National Bioethics Commission, Bethesda, Maryland, April 2001, Vol. II,  p. B-9 and B-27

 27. Ethical and Policy Issues in International Research:  Clinical trials in Developing Countries. Report and Recommendations of the National Bioethics Commission, Bethesda, Maryland, April 2001, Vol. I,  p. ii and iii

 28.  International Ethical Guidelines for Biomedical Research Involving Human Subjects, prepared by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO), Geneva 1993

 29. Nuremberg Code, adopted by the U. S. Tribunal on 19 July, 1947, Principle No.1 

 30.  Rogeer Hoedemaekers and Hank ten have “Commercialisation of genetic diagnostic services” Medicine, Healthcare and Philosophy 1: 217-224, 1998

 31. Bernard M. Dickens. “The Challenge of Equivalent Protection” Commissioned Paper. Ethical and Policy Issues in International Research:  Clinical trials in Developing Countries. Report and Recommendations of the National Bioethics Commission, Bethesda, Maryland, April 2001, Vol. II,  p. A-7 

 32.  General Statement, in the Ethical Guidelines for Biomedical Research on Human Subjects”, ICMR, New Delhi, 2000

 33.  Principle 18 of Fundamental Principles of Research on the Human Genome, Bioethics Committee, Council for science and Technology, Japan, 14 June 2000

 

34.  Para. 19 Ethical Principles for Medical Research Involving Human Subjects, adopted by the 52nd General Assembly of World Medical Association, Edinburgh, Scotland, October, 2000)

 35. Ethical Considerations in HIV Preventive Vaccine Research,  UNAIDS Guidance Document, May, 2000,  commentary on Guidance point 7

 36.  The Goals of Medicine Setting New Priorities, Special Supplement, Hastings Center Report, November-December 1996 

 37.  Jeffrey Kahn “Research Ethics: Then, Now, and Again”, Bioethics Examiner, Winter 1998, Vol 1, Issue 6

 38.  Dr. Ames Dhai, Clinical Research In  Africa: Ethics, Culture and the Law. The EFGCP News, The News letter of European Forum for Good Clinical Practice. Summer 2002)

 39.  Tri-Council Policy Statement, “Ethical Conduct for Research Involving Humans”, Canada, August 1998

 40.  The Australian National Statement on Ethical Conduct in Research Involving Humans, June 1999

 41.  Guidelines on Ethical Matters in Aboriginals and Torres Strait Islander Health Research, National Health and Medical Research Council, Australia, June,1991)

 42.  The ethics of clinical research in developing countries, a discussion paper. Nuffield Council of Bioethics, October 1999

 43.  The ethics of research related to healthcare in developing countries” Nuffield Council of Bioethics. April 2002 

 44.  Ethical Considerations in HIV Preventive Vaccine Research, UNAIDS Guidance Document, May, 2000, p9

 45.  Rober Bickerstaffe and Daniel Brasseur, The EFGCP News, The Newsletter of the European Forum for Good Clinical Practice, Autumn 2002

 46.  Surveying and Evaluating Ethical Review Practices, a complementary guideline to the Operational Guidelines for Ethics Committees That Review Biomedical Research, WHO, Geneva February 2002

 47.   Charter of the United Nations; June 26, 1945, Preamble

 48.  Bodenheimer T. Uneasy  alliance. Clinical investigators and the Pharmaceutical industry. N.  Engl. J. Med 2000;342::1539-1544, quoted  in CAHTA’s Newsletter, Issue 25, January 2002 

 

 

Comments